Business · Companies · 3 hrs ago
Isomorphic Labs raises $5 billion to advance AI-designed drugs
London-based Isomorphic Labs raised $5 billion in a new funding round led by Greenoaks and Sequoia Capital.
The company is a spinout from Alphabet’s DeepMind and uses artificial intelligence to help design drugs.
The funding follows a $2.1 billion round in May, giving the company two of the biotech sector’s largest funding rounds this year.
Isomorphic says its work has produced positive early test results in cancer and immune-system research.
It plans to develop its technology and move drug candidates toward clinical trials, while also exploring more areas of biology.
No AI-designed medicine has been approved, and drug development remains uncertain, so the funding does not mean a treatment is ready for patients.
Isomorphic Labs announced a $5 billion Series C funding round on November 17, 2026.
The London-based AI drug discovery company said it aims to use the funding to develop its drug-design engine and move drug candidates toward clinical trials.
The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and existing investors also participating.
The funding follows a $2.1 billion Series B announced in May.
Isomorphic said it had seen positive preclinical results in oncology and immunology.
- Who
- Isomorphic Labs, an AI drug discovery company spun out of Alphabet’s DeepMind.
- What
- It raised $5 billion in a Series C funding round.
- When
- November 17, 2026.
- Where
- London-based; the funding round’s location is Not stated.
- Why
- To continue developing its drug-design engine, pursue more types of medicine and move drug candidates toward clinical trials.
This story does not have two clearly opposing sides.
Isomorphic announced a $2.1 billion Series B round.
Isomorphic announced the closing of its $5 billion Series C round.
- Series C funding
- $5 billion
- Lead investors
- Greenoaks and Sequoia Capital
- Previous round
- $2.1 billion Series B announced in May 2026
- Company base
- London
- Preclinical results
- Oncology and immunology
4 sources
What people are saying
expand deeper into new biology
setting the stage for clinical entry